Shanna Kulick
Family · Hazleton, PANPI 1578233102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $2,186, more than ten times the $103 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$715
- AbbVie$614
- AstraZeneca$473
- Lilly USA, LLC$393
- Amgen$345
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$282
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,09898%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $715 |
| AbbVie | 36 | $614 |
| AstraZeneca | 27 | $473 |
| Lilly USA, LLC | 23 | $393 |
| Amgen | 24 | $345 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $282 |
| Pfizer | 16 | $258 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $185 |
| Bayer | 9 | $172 |
| Boehringer Ingelheim | 7 | $129 |
| Merck | 7 | $121 |
| Seagen Inc. | 1 | $80 |
| Inspire Medical Systems, Inc. | 1 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Paratek Pharmaceuticals, Inc. | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Novartis | 2 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| GSK | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
| Medtronic | 1 | $12 |
How this compares
$4,178 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $53,423 |
| OzempicSemaglutide | 29 | $35,138 |
| JardianceEmpagliflozin | 31 | $34,836 |
| MounjaroTirzepatide | 17 | $21,451 |
| XareltoRivaroxaban | 15 | $14,564 |
| FarxigaDapagliflozin Propanediol | 13 | $12,461 |
| Repatha SureclickEvolocumab | 13 | $12,280 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $9,564 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $8,126 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,158 |
| Mesalamine | 12 | $3,858 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,799 |
| Carbamazepine ErCarbamazepine | 13 | $2,425 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,079 |
| Gabapentin | 87 | $1,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $258 | $53,42373 claims |
| Novo NordiskOzempic, Novolog | $715 | $36,32540 claims |
| Boehringer IngelheimJardiance | $129 | $34,83631 claims |
| Lilly USA, LLCMounjaro | $393 | $21,45117 claims |
| Johnson & JohnsonXarelto | $18 | $14,56415 claims |
| AstraZenecaFarxiga | $473 | $12,46113 claims |
| GSKAnoro Ellipta | $13 | $8,12612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Hazleton
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.